BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 23274564)

  • 1. Minocycline inhibits malignant ascites of ovarian cancer through targeting multiple signaling pathways.
    Pourgholami MH; Ataie-Kachoie P; Badar S; Morris DL
    Gynecol Oncol; 2013 Apr; 129(1):113-9. PubMed ID: 23274564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice.
    Pourgholami MH; Yan Cai Z; Lu Y; Wang L; Morris DL
    Clin Cancer Res; 2006 Mar; 12(6):1928-35. PubMed ID: 16551879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minocycline suppresses interleukine-6, its receptor system and signaling pathways and impairs migration, invasion and adhesion capacity of ovarian cancer cells: in vitro and in vivo studies.
    Ataie-Kachoie P; Morris DL; Pourgholami MH
    PLoS One; 2013; 8(4):e60817. PubMed ID: 23593315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of cell proliferation, vascular endothelial growth factor and tumor growth by albendazole.
    Pourgholami MH; Cai ZY; Wang L; Badar S; Links M; Morris DL
    Cancer Invest; 2009 Feb; 27(2):171-7. PubMed ID: 19235589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer.
    Hasumi Y; Mizukami H; Urabe M; Kohno T; Takeuchi K; Kume A; Momoeda M; Yoshikawa H; Tsuruo T; Shibuya M; Taketani Y; Ozawa K
    Cancer Res; 2002 Apr; 62(7):2019-23. PubMed ID: 11929819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model.
    Byrne AT; Ross L; Holash J; Nakanishi M; Hu L; Hofmann JI; Yancopoulos GD; Jaffe RB
    Clin Cancer Res; 2003 Nov; 9(15):5721-8. PubMed ID: 14654557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
    Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
    Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN.
    De Cesare M; Sfondrini L; Campiglio M; Sommariva M; Bianchi F; Perego P; van Rooijen N; Supino R; Rumio C; Zunino F; Pratesi G; Tagliabue E; Balsari A
    J Immunother; 2010 Jan; 33(1):8-15. PubMed ID: 19952960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Signal mechanisms of vascular endothelial growth factor and interleukin-8 in ovarian hyperstimulation syndrome: dopamine targets their common pathways.
    Chen SU; Chou CH; Lin CW; Lee H; Wu JC; Lu HF; Chen CD; Yang YS
    Hum Reprod; 2010 Mar; 25(3):757-67. PubMed ID: 20008399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-Hydroxy estradiol but not 2-hydroxy estradiol induces expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor A through phosphatidylinositol 3-kinase/Akt/FRAP pathway in OVCAR-3 and A2780-CP70 human ovarian carcinoma cells.
    Gao N; Nester RA; Sarkar MA
    Toxicol Appl Pharmacol; 2004 Apr; 196(1):124-35. PubMed ID: 15050414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells.
    Merighi S; Benini A; Mirandola P; Gessi S; Varani K; Simioni C; Leung E; Maclennan S; Baraldi PG; Borea PA
    Mol Pharmacol; 2007 Aug; 72(2):395-406. PubMed ID: 17488804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (-)-Epigallocatechin-3-gallate inhibits human papillomavirus (HPV)-16 oncoprotein-induced angiogenesis in non-small cell lung cancer cells by targeting HIF-1α.
    He L; Zhang E; Shi J; Li X; Zhou K; Zhang Q; Le AD; Tang X
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):713-25. PubMed ID: 23292117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
    Garofalo A; Naumova E; Manenti L; Ghilardi C; Ghisleni G; Caniatti M; Colombo T; Cherrington JM; Scanziani E; Nicoletti MI; Giavazzi R
    Clin Cancer Res; 2003 Aug; 9(9):3476-85. PubMed ID: 12960140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
    Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
    Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer.
    Lo CW; Chen MW; Hsiao M; Wang S; Chen CA; Hsiao SM; Chang JS; Lai TC; Rose-John S; Kuo ML; Wei LH
    Cancer Res; 2011 Jan; 71(2):424-34. PubMed ID: 21123455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.
    Hu L; Hofmann J; Holash J; Yancopoulos GD; Sood AK; Jaffe RB
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6966-71. PubMed ID: 16203789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix protein of vesicular stomatitis virus: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation.
    Zhou Y; Wen F; Zhang P; Tang R; Li Q
    Cancer Gene Ther; 2013 Mar; 20(3):178-85. PubMed ID: 23449478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis.
    Shirakami Y; Shimizu M; Adachi S; Sakai H; Nakagawa T; Yasuda Y; Tsurumi H; Hara Y; Moriwaki H
    Cancer Sci; 2009 Oct; 100(10):1957-62. PubMed ID: 19558547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model.
    Yoshiji H; Kuriyama S; Hicklin DJ; Huber J; Yoshii J; Ikenaka Y; Noguchi R; Nakatani T; Tsujinoue H; Fukui H
    Hepatology; 2001 Apr; 33(4):841-7. PubMed ID: 11283848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.